PE20061100A1 - 6-DIMETHYLAMINOMETHYL-1- (3-METOXYPHENYL) -1,3-DIHYDROXYCLYCLOHEXANE PHOSPHATE SALTS - Google Patents
6-DIMETHYLAMINOMETHYL-1- (3-METOXYPHENYL) -1,3-DIHYDROXYCLYCLOHEXANE PHOSPHATE SALTSInfo
- Publication number
- PE20061100A1 PE20061100A1 PE2006000228A PE2006000228A PE20061100A1 PE 20061100 A1 PE20061100 A1 PE 20061100A1 PE 2006000228 A PE2006000228 A PE 2006000228A PE 2006000228 A PE2006000228 A PE 2006000228A PE 20061100 A1 PE20061100 A1 PE 20061100A1
- Authority
- PE
- Peru
- Prior art keywords
- dimethylaminomethyl
- dihydroxyclyclohexane
- metoxyphenyl
- compound
- phosphate salts
- Prior art date
Links
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical class [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 150000003016 phosphoric acids Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE COMPUESTOS 6-DIMETILAMINOMETIL-1-(3-METOXIFENIL)-1,3-DIHIDROXICLICLOHEXANO DE FORMULA (I), EN DONDE R1 ES OH, R2 ES OH Y R3 ES H; O R3 ES OH Y R2 ES H; Y R4 ES CH3; LOS CUALES SE PRESENTAN EN FORMA DE SUS SALES DE ACIDO FOSFORICO PREFERENTEMENTE DIFOSFORICOS Y/O ORTOFOSFORICOS; SIENDO PREFERIDO LA SAL DE ORTOFOSFATO DEL COMPUESTO RACEMICO (1RS,3RS,6RS)-6-DIMETILAMINOMETIL-1-(3-METOXIFENIL)-CLICLOHEXAN-1,3-DIOL. UN PROCESO DE PREPARACION DE DICHAS SALES QUE COMPRENDE EN HACER REACCIONAR EL CLORHIDRATO DEL COMPUESTO (I) O SU BASE LIBRE, EN ACIDO FOSFORICO EN UNA RELACION MOLAR DE 2:1 HASTA 1:2. TAMBIEN SE REFIERE A LOS POLIMORFOS DE LAS FORMAS A, B, C Y AMORFO DE LA SAL ORTOFOSFATO DEL COMPUESTO Y PROCEDIMIENTOS DE OBTENCION DE DICHOS POLIMORFOS; Y UNA COMPOSICON FARMACEUTICA PARA EL TRATAMIENTO DEL DOLOR, MIGRANA, DEPRESION Y ENFERMEDADES NEURODEGENERATIVAS6-DIMETHYLAMINOMETHYL-1- (3-METOXYPHENYL) -1,3-DIHYDROXYCLYCLOHEXANE COMPOUNDS OF FORMULA (I), WHERE R1 IS OH, R2 IS OH AND R3 IS H; OR R3 IS OH AND R2 IS H; AND R4 IS CH3; WHICH ARE PRESENTED IN THE FORM OF THEIR PHOSPHORIC ACID SALTS, PREFERENTIALLY DIPHOSPHORIC AND / OR ORTHOPHOSPHORIC; THE ORTHOPHOSPHATE SALT OF THE RACEMIC COMPOUND (1RS, 3RS, 6RS) -6-DIMETHYLAMINOMETHYL-1- (3-METOXIFENIL) -CLICLOHEXAN-1,3-DIOL being preferred. A PROCESS FOR THE PREPARATION OF SUCH SALTS WHICH INCLUDES IN REACTING THE HYDROCHLORIDE OF THE COMPOUND (I) OR ITS FREE BASE, IN PHOSPHORIC ACID IN A MOLAR RATIO OF 2: 1 TO 1: 2. IT ALSO REFERS TO THE POLYMORPHES OF FORMS A, B, C AND AMORPHO OF THE SALT ORTHOPHOSPHATE OF THE COMPOUND AND PROCEDURES FOR OBTAINING SAID POLYMORPHES; AND A PHARMACEUTICAL COMPOSICON FOR THE TREATMENT OF PAIN, MIGRANE, DEPRESSION AND NEURODEGENERATIVE DISEASES
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005009217A DE102005009217A1 (en) | 2005-02-25 | 2005-02-25 | New phosphoric acid salts of 6-dimethylaminomethyl -1-(3-methoxyphenyl)-1,3-dihydroxycyclohexane useful to treat e.g. pain, migraine, depressions, neurodegenerative illnesses, cognitive illnesses, fear conditions and epilepsy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20061100A1 true PE20061100A1 (en) | 2007-01-04 |
Family
ID=36090780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006000228A PE20061100A1 (en) | 2005-02-25 | 2006-02-27 | 6-DIMETHYLAMINOMETHYL-1- (3-METOXYPHENYL) -1,3-DIHYDROXYCLYCLOHEXANE PHOSPHATE SALTS |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1851191A1 (en) |
| JP (1) | JP2008531510A (en) |
| KR (1) | KR20070107162A (en) |
| CN (1) | CN101137615A (en) |
| AR (1) | AR053145A1 (en) |
| AU (1) | AU2006218132B2 (en) |
| BR (1) | BRPI0606146A2 (en) |
| CA (1) | CA2598845A1 (en) |
| DE (1) | DE102005009217A1 (en) |
| IL (1) | IL185468A0 (en) |
| MX (1) | MX2007010361A (en) |
| NO (1) | NO20074673L (en) |
| NZ (1) | NZ556338A (en) |
| PE (1) | PE20061100A1 (en) |
| RU (1) | RU2007135271A (en) |
| TW (1) | TW200640840A (en) |
| WO (1) | WO2006089707A1 (en) |
| ZA (1) | ZA200708153B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080039400A (en) | 2005-07-07 | 2008-05-07 | 파남 컴퍼니스 인크. | Sustained-release pharmaceutical composition of the high water-soluble drug |
| DE102007022790A1 (en) * | 2007-05-11 | 2008-11-20 | Grünenthal GmbH | Axomadol for the treatment of pain in osteoarthritis |
| WO2011029614A1 (en) * | 2009-09-14 | 2011-03-17 | Grünenthal GmbH | Crystalline modifications of 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19525137C2 (en) * | 1995-07-11 | 2003-02-27 | Gruenenthal Gmbh | 6-Dimethylaminomethyl-1-phenyl-cyclohexane compounds as intermediates for the preparation of pharmaceutical agents |
| DE10146275A1 (en) * | 2001-09-18 | 2003-04-24 | Gruenenthal Gmbh | Combination of selected opioids with muscarinic antagonists for the treatment of urinary incontinence |
| DE10333835A1 (en) * | 2003-07-24 | 2005-03-10 | Gruenenthal Gmbh | Sustained-release drug containing 6-dimethylaminomethyl-1- (3-methoxy-phenyl) -cyclohexane-1,3-diol |
-
2005
- 2005-02-25 DE DE102005009217A patent/DE102005009217A1/en not_active Withdrawn
-
2006
- 2006-02-10 TW TW095104476A patent/TW200640840A/en unknown
- 2006-02-21 JP JP2007556542A patent/JP2008531510A/en not_active Withdrawn
- 2006-02-21 NZ NZ556338A patent/NZ556338A/en not_active IP Right Cessation
- 2006-02-21 EP EP06707123A patent/EP1851191A1/en not_active Withdrawn
- 2006-02-21 CA CA002598845A patent/CA2598845A1/en not_active Abandoned
- 2006-02-21 AU AU2006218132A patent/AU2006218132B2/en not_active Ceased
- 2006-02-21 RU RU2007135271/04A patent/RU2007135271A/en not_active Application Discontinuation
- 2006-02-21 WO PCT/EP2006/001547 patent/WO2006089707A1/en not_active Ceased
- 2006-02-21 KR KR1020077021974A patent/KR20070107162A/en not_active Ceased
- 2006-02-21 CN CNA2006800059649A patent/CN101137615A/en active Pending
- 2006-02-21 BR BRPI0606146-0A patent/BRPI0606146A2/en not_active IP Right Cessation
- 2006-02-21 MX MX2007010361A patent/MX2007010361A/en not_active Application Discontinuation
- 2006-02-24 AR ARP060100684A patent/AR053145A1/en not_active Application Discontinuation
- 2006-02-27 PE PE2006000228A patent/PE20061100A1/en not_active Application Discontinuation
-
2007
- 2007-08-23 IL IL185468A patent/IL185468A0/en unknown
- 2007-09-13 NO NO20074673A patent/NO20074673L/en not_active Application Discontinuation
- 2007-09-21 ZA ZA200708153A patent/ZA200708153B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO20074673L (en) | 2007-10-19 |
| NZ556338A (en) | 2009-11-27 |
| WO2006089707A1 (en) | 2006-08-31 |
| TW200640840A (en) | 2006-12-01 |
| ZA200708153B (en) | 2008-10-29 |
| JP2008531510A (en) | 2008-08-14 |
| AU2006218132B2 (en) | 2011-10-06 |
| MX2007010361A (en) | 2008-02-21 |
| EP1851191A1 (en) | 2007-11-07 |
| CN101137615A (en) | 2008-03-05 |
| AU2006218132A1 (en) | 2006-08-31 |
| DE102005009217A1 (en) | 2006-08-31 |
| AR053145A1 (en) | 2007-04-25 |
| BRPI0606146A2 (en) | 2009-06-02 |
| RU2007135271A (en) | 2010-02-27 |
| IL185468A0 (en) | 2008-01-06 |
| KR20070107162A (en) | 2007-11-06 |
| CA2598845A1 (en) | 2006-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022013974A (en) | Sos1 inhibitor containing phosphorus. | |
| MX2021006421A (en) | AMINO ACID ANILIDES AS SMALL MOLECULE MODULATORS OF INTERLEUKINS-17 (IL-17). | |
| AR038047A1 (en) | THERAPEUTIC AGENTS | |
| ECSP066730A (en) | COMPOUNDS AND PROCEDURES FOR USE | |
| UY30408A1 (en) | SUBSTITUTED DERIVATIVES OF THE ACETATE OF 8- (4-METOXIFENIL) -2,3,4,8-TETRAHYDROIMIDAZO- [1,5-A] -PIRIMIDIN-6-AMINA, PHARMACEUTICAL COMPOSITIONS AND APPLICATIONS | |
| CO5580820A2 (en) | NEW ACID DERIVATIVES (2S) -3- (4- {2- [AMINO] -2-OXOETOXI} PHENYL) -2-ETOXIPROPANOIC PROCESSES FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| UY30377A1 (en) | FUSIONATED TRICYCLE INHIBITORS OF SULFONAMIDE OF GAMA-SECRETASA | |
| CO6290683A2 (en) | HETEROCICLIC IMIDAZOLINE PIRIDO COMPOUNDS AND THEIR COMPOSITIONS AS C-MET INHIBITORS | |
| UY31384A1 (en) | NEW HETEROCICLIC COMPOUNDS FOR THE INHIBITION OF PROTEIN KINASE B | |
| GT200500060A (en) | IMIDAZOL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | |
| UY28369A1 (en) | THERAPEUTIC AGENTS | |
| ECSP066383A (en) | DERIVATIVES OF 5-PHENYL-4-METHYL-TIAZOL-2-IL-AMINA AS INHIBITORS OF KINASA ENZYMES PHOSFATIDILINOSITOL 3 (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE RESPIRATORY ROUTES | |
| AR063923A1 (en) | SALTS OF ZOLEDRONIC ACID, PREPARATION PROCESSES AND COMPOSITIONS | |
| BRPI0717794B8 (en) | 3-amino-1-propanesulfonic acid compound and pharmaceutical composition | |
| ECSP088587A (en) | PIPERIDINE COMPOUNDS 3,5-REPLACED AS RENINE INHIBITORS | |
| CR9954A (en) | PIRAZINE DERIVATIVES | |
| UY31885A (en) | DERIVED FROM THE 1, 3, 5-TRIAZINA-2, 4-DIAMINAS-6-SUBSTITUTED-N-SUBSTITUTED AND PHARMACEUTICALLY ACCEPTABLE SALTS OF THE SAME, COMPOSITIONS AND APPLICATIONS. | |
| UY28333A1 (en) | CASPASA INHIBITORS AND THEIR USES. | |
| ECSP088700A (en) | 4-PHENYL-TIAZOL-5-CARBOXILIC ACIDS AND 4-PHENYL-TIAZOL-5-CARBOXILIC ACIDS AS INHIBITORS OF THE PLK1 | |
| UY28896A1 (en) | POWDER FORMULATIONS FOR INHALATION, WHICH CONTAIN BETA-ENANTIOMERALLY PURE AGONISTS | |
| AR076181A1 (en) | COMPOUNDS DERIVED FROM MENTOL AND USE OF THE SAME AS ORAL AND SYSTEMIC ACTIVE AGENTS. METHOD. COMPOSITION. | |
| BR112022010181A2 (en) | TRIHETEROCYCLIC COMPOUND AS A JAK INHIBITOR AND USE OF IT | |
| AR131735A1 (en) | THERAPEUTIC AGENTS | |
| PE20061100A1 (en) | 6-DIMETHYLAMINOMETHYL-1- (3-METOXYPHENYL) -1,3-DIHYDROXYCLYCLOHEXANE PHOSPHATE SALTS | |
| ECSP066964A (en) | NEW BETA-AGONISTS, PROCEDURE FOR PREPARATION AND USE AS MEDICATIONS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |